4 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
To confirm the safety of the Articulinx implant by evaluating device and procedure related adverse events.
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
To determine the effectiveness of the HEART (History, Electrocardiogram (ECG), Age, Risk factors, Troponin) score with POC hs-cTnI testing by ambulance nurses in safely ruling out ACS and increasing the number of patients left at home after…